138 related articles for article (PubMed ID: 19097670)
1. Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
van Putte BP; Grootenboers M; van Boven WJ; van Oosterhout M; Pasterkamp G; Folkerts G; Schramel F
Lung Cancer; 2009 Aug; 65(2):208-13. PubMed ID: 19097670
[TBL] [Abstract][Full Text] [Related]
2. Selective pulmonary artery perfusion followed by blood flow occlusion: new challenge for the treatment of pulmonary malignancies.
Grootenboers MJ; Schramel FM; van Boven WJ; Hendriks JM; van Schil PE; De Wit PE; Pasterkamp G; Folkerts G; van Putte BP
Lung Cancer; 2009 Mar; 63(3):400-4. PubMed ID: 18657338
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of gemcitabine when delivered by selective pulmonary artery perfusion for the treatment of lung cancer.
van Putte BP; Grootenboers M; van Boven WJ; Hendriks JM; van Schil PE; Guetens G; De Boeck G; Pasterkamp G; Schramel F; Folkerts G
Drug Metab Dispos; 2008 Apr; 36(4):676-81. PubMed ID: 18187564
[TBL] [Abstract][Full Text] [Related]
4. Selective pulmonary artery perfusion with melphalan is equal to isolated lung perfusion but superior to intravenous melphalan for the treatment of sarcoma lung metastases in a rodent model.
Den Hengst WA; Hendriks JM; Van Hoof T; Heytens K; Guetens G; de Boeck G; Lardon F; Van Schil PE
Eur J Cardiothorac Surg; 2012 Aug; 42(2):341-7; discussion 347. PubMed ID: 22345285
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
[TBL] [Abstract][Full Text] [Related]
6. A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Soo RA; Wang LZ; Tham LS; Yong WP; Boyer M; Lim HL; Lee HS; Millward M; Liang S; Beale P; Lee SC; Goh BC
Ann Oncol; 2006 Jul; 17(7):1128-33. PubMed ID: 16670205
[TBL] [Abstract][Full Text] [Related]
7. Selective Pulmonary Artery Perfusion With Blood Flow Occlusion Delivers Concentrated Levels of Chemotherapy to Ipsilateral Hilar and Mediastinal Lymph Nodes.
Sparks PJ; Hines J; Lowry J; Strode M; Roach M
World J Oncol; 2014 Feb; 5(1):1-6. PubMed ID: 29147370
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Wang L; Wu X; Huang M; Cai J; Xu N; Liu J
Cancer Chemother Pharmacol; 2007 Jul; 60(2):211-8. PubMed ID: 17124596
[TBL] [Abstract][Full Text] [Related]
9. A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Masters GA; Argiris AE; Hahn EA; Beck JT; Rausch PG; Ye Z; Monberg MJ; Bloss LP; Curiel RE; Obasaju CK
J Thorac Oncol; 2006 Jan; 1(1):19-24. PubMed ID: 17409822
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine in brief versus prolonged low-dose infusion, both combined with carboplatin for advanced non-small cell lung cancer.
Beniwal SK; Patel KM; Shukla S; Parikh BJ; Shah S; Patel A
Indian J Cancer; 2012; 49(2):202-8. PubMed ID: 23107971
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Ng EW; Sandler AB; Robinson L; Einhorn LH
Am J Clin Oncol; 1999 Dec; 22(6):550-3. PubMed ID: 10597737
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
Van Putte BP; Hendriks JM; Romijn S; Pauwels B; Vermorken JB; Van Schil PE
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):125-30. PubMed ID: 15999051
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Ritch P; Rudin CM; Bitran JD; Edelman MJ; Makalinao A; Irwin D; Lilenbaum R; Peterson P; John WJ
Lung Cancer; 2006 May; 52(2):173-80. PubMed ID: 16507327
[TBL] [Abstract][Full Text] [Related]
14. A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer.
Tognoni A; Pensa F; Vaira F; Vigani A; Caness P; Sinaccio G; Pronzato P
J Chemother; 2002 Jun; 14(3):296-300. PubMed ID: 12120886
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Davies AM; Ruel C; Lara PN; Lau DH; Gumerlock PH; Bold R; Shibata S; Lenz HJ; Schenkein DP; Gandara DR
J Thorac Oncol; 2008 Jan; 3(1):68-74. PubMed ID: 18166843
[TBL] [Abstract][Full Text] [Related]
16. Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Wu ZY; Guan HH; Lin ZX; Yang HK; Zhou L; Cai QC
J Chemother; 2014 Oct; 26(5):306-11. PubMed ID: 24075685
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Leijen S; Veltkamp SA; Huitema AD; van Werkhoven E; Beijnen JH; Schellens JH
Gynecol Oncol; 2013 Sep; 130(3):511-7. PubMed ID: 23665458
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
[TBL] [Abstract][Full Text] [Related]
19. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Grønberg BH; Bremnes RM; Fløtten O; Amundsen T; Brunsvig PF; Hjelde HH; Kaasa S; von Plessen C; Stornes F; Tollåli T; Wammer F; Aasebø U; Sundstrøm S
J Clin Oncol; 2009 Jul; 27(19):3217-24. PubMed ID: 19433683
[TBL] [Abstract][Full Text] [Related]
20. Selective pulmonary artery perfusion: a novel method for the treatment of pulmonary malignancies.
Grootenboers MJ; Schramel FM; Hendriks JM; Van Boven WJ; Van Schil PE; Van Putte BP
Acta Chir Belg; 2007; 107(4):361-7. PubMed ID: 17966526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
